CTLA4 and colitis: Patients with ICI colitis who underwent combined anti-CTLA4 and anti-PD1 therapy exhibited an enrichment of bone marrow-derived cells, notably inflammatory DCs, alongside a reduction in CD4+ tissue-resident memory T cells.